STOPCAP

What was this study about?

We want to find out which treatments for metastatic hormone-sensitive prostate cancer are the most effective, and for which men.  We will do this by combining results and (anonymous) patient data from clinical trials to find out which characteristics of a man and his cancer are most useful for predicting his prognosis and his response to treatments.

We will also look for reliable early measures of whether a treatment is working, which can be used to shorten future trials, so men can access newer treatments sooner than they do now.

Finally, we will also try to ensure that the most effective treatments are used in clinical practice.

The STOPCAP Programme has been ongoing since 2018.

For more information, visit:

• STOPCAP website
• STOPCAP protocols
• Prostate Cancer UK project page

What difference did this study make?

Please click below for more information about STOPCAP results, so far:

• Docetaxel, systematic review and aggregate data meta-analysis (Lancet Onc 2016)
• Bisphosphonates, systematic review and aggregate data meta-analysis (Lancet Onc 2016)
• Abiraterone, systematic review and aggregate data meta-analysis, (EJC 2017)
• Aggregate data network meta-analysis, (Annals Onc 2018) 
• Prostate RT, systematic review and aggregate data meta-analysis, (Eur Urol 2019)
• Docetaxel, systematic review and individual participant data meta-analysis (Lancet Onc 2023) 

 

Type of study

Meta-analyses

Contact details

mrcctu.stopcapm1@ucl.ac.uk

Who funded the study?

STOPCAP is funded by Prostate Cancer UK.